Bayer Extends Xarelto Investigation to 275,000 Patients, Report

September 2, 2014 6:22 PM

4 0

Bayer Extends Xarelto Investigation to 275,000 Patients, Report

Bayer AG’s (ADR) (BAYRY) subgroup Bayer HealthCare announced positive results from the second Phase-III X-VeRT study of its “oral anticoagulant” Xarelto (Rivaroxaban) today. The results revealed that a daily dosage of Xarelto is an “effective and well-tolerated alternative” to Vitamin K Antagonists (VKAs) for patients suffering from non-Valvular Atrial Fibrillation and undergoing cardioversion.

X-VeRT, the first prospective trial of a novel oral anticoagulant, showed that compared with the use of VKA, rivaroxaban was associated with a numerical reduction in the risk of cardiovascular events of 50 per cent in the composite primary efficacy outcome of stroke, transient ischemic attack, perip...

Read more

To category page

Loading...